Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis.

Autor: Wenk C; Department of Medicine III, Technische Universität München, Munich, Germany., Garz AK; Department of Medicine III, Technische Universität München, Munich, Germany., Grath S; Department of Biology II, Ludwig-Maximilians-Universität München, Munich, Germany., Huberle C; Department of Medicine III, Technische Universität München, Munich, Germany., Witham D; Department of Medicine III, Technische Universität München, Munich, Germany., Weickert M; Department of Medicine III, Technische Universität München, Munich, Germany., Malinverni R; Josep Carreras Leukaemia Research Institute, Campus ICO-Germany Trias I Pujol-Universidad Autonoma de Barcelona, Badalona, Spain.; Program for Predictive and Personalized Medicine of Cancer, Germans Trias i Pujol Research Institute, Badalona, Spain., Niggemeyer J; Laboratory for Leukemia Diagnostics, Department of Medicine III, Ludwig-Maximilians-Universität München, Munich, Germany., Kyncl M; Department of Medicine III, Technische Universität München, Munich, Germany., Hecker J; Department of Medicine III, Technische Universität München, Munich, Germany., Pagel C; Department of Medicine III, Technische Universität München, Munich, Germany., Mulholland CB; Department of Biology II, Ludwig-Maximilians-Universität München, Munich, Germany., Müller-Thomas C; Department of Medicine III, Technische Universität München, Munich, Germany., Leonhardt H; Department of Biology II, Ludwig-Maximilians-Universität München, Munich, Germany., Bassermann F; Department of Medicine III, Technische Universität München, Munich, Germany.; German Cancer Consortium, Heidelberg, Germany; and.; German Cancer Center, Heidelberg, Germany., Oostendorp RAJ; Department of Medicine III, Technische Universität München, Munich, Germany., Metzeler KH; Laboratory for Leukemia Diagnostics, Department of Medicine III, Ludwig-Maximilians-Universität München, Munich, Germany.; German Cancer Consortium, Heidelberg, Germany; and.; German Cancer Center, Heidelberg, Germany., Buschbeck M; Josep Carreras Leukaemia Research Institute, Campus ICO-Germany Trias I Pujol-Universidad Autonoma de Barcelona, Badalona, Spain.; Program for Predictive and Personalized Medicine of Cancer, Germans Trias i Pujol Research Institute, Badalona, Spain., Götze KS; Department of Medicine III, Technische Universität München, Munich, Germany.; German Cancer Consortium, Heidelberg, Germany; and.; German Cancer Center, Heidelberg, Germany.

Publikováno v: Blood advances [Blood Adv] 2018 Dec 11; Vol. 2 (23), pp. 3447-3461.

The target landscape of clinical kinase drugs.

Autor: Klaeger S; Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Heinzlmeir S; Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Wilhelm M; Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany., Polzer H; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Internal Medicine III, University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany., Vick B; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Apoptosis in Hematopoietic Stem Cells, Helmholtz Center Munich, German Center for Environmental Health (HMGU), Munich, Germany., Koenig PA; Institut für Klinische Chemie und Pathobiochemie, TUM, Munich, Germany., Reinecke M; Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Ruprecht B; Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany., Petzoldt S; Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Meng C; Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany., Zecha J; Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Reiter K; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Internal Medicine III, University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany., Qiao H; Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany., Helm D; Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany., Koch H; Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Schoof M; Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany., Canevari G; Oncology, Nerviano Medical Sciences Srl, Milan, Italy., Casale E; Oncology, Nerviano Medical Sciences Srl, Milan, Italy., Depaolini SR; Oncology, Nerviano Medical Sciences Srl, Milan, Italy., Feuchtinger A; Research Unit Analytical Pathology, Helmholtz Zentrum München, Neuherberg, Germany., Wu Z; Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany., Schmidt T; Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany., Rueckert L; SAP SE, Potsdam, Germany., Becker W; SAP SE, Potsdam, Germany., Huenges J; SAP SE, Potsdam, Germany., Garz AK; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Medicine III, Klinikum rechts der Isar, TUM, Munich, Germany., Gohlke BO; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Structural Bioinformatics Group, Charité-Universitätsmedizin, Berlin, Germany., Zolg DP; Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany., Kayser G; Institute of Surgical Pathology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Vooder T; Center of Thoracic Surgery, Krefeld, Germany.; Estonian Genome Center, University of Tartu, Tartu, Estonia.; Tartu University Hospital, Tartu, Estonia., Preissner R; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Structural Bioinformatics Group, Charité-Universitätsmedizin, Berlin, Germany., Hahne H; Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany., Tõnisson N; Estonian Genome Center, University of Tartu, Tartu, Estonia.; Tartu University Hospital, Tartu, Estonia., Kramer K; Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany., Götze K; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Medicine III, Klinikum rechts der Isar, TUM, Munich, Germany., Bassermann F; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Medicine III, Klinikum rechts der Isar, TUM, Munich, Germany., Schlegl J; SAP SE, Walldorf, Germany., Ehrlich HC; SAP SE, Potsdam, Germany., Aiche S; SAP SE, Potsdam, Germany., Walch A; Research Unit Analytical Pathology, Helmholtz Zentrum München, Neuherberg, Germany., Greif PA; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Internal Medicine III, University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany., Schneider S; Department of Chemistry, TUM, Garching, Germany.; Center For Integrated Protein Science Munich (CIPSM), Munich, Germany., Felder ER; Oncology, Nerviano Medical Sciences Srl, Milan, Italy., Ruland J; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Institut für Klinische Chemie und Pathobiochemie, TUM, Munich, Germany., Médard G; Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany., Jeremias I; German Cancer Consortium (DKTK), Heidelberg, Germany.; Department of Apoptosis in Hematopoietic Stem Cells, Helmholtz Center Munich, German Center for Environmental Health (HMGU), Munich, Germany.; Department of Pediatrics, Dr von Hauner Children's Hospital, LMU, Munich, Germany., Spiekermann K; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Internal Medicine III, University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany., Kuster B; Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany. kuster@tum.de.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Center For Integrated Protein Science Munich (CIPSM), Munich, Germany.; Bavarian Biomolecular Mass Spectrometry Center (BayBioMS), TUM, Freising, Germany.

Publikováno v: Science (New York, N.Y.) [Science] 2017 Dec 01; Vol. 358 (6367).

Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.

Autor: Eichner R; Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany., Heider M; Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany., Fernández-Sáiz V; Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., van Bebber F; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany., Garz AK; Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Lemeer S; Department of Proteomics and Bioanalytics, Technische Universität München, Freising, Germany., Rudelius M; Institute of Pathology, Universität Würzburg, Würzburg, Germany.; Comprehensive Cancer Center Mainfranken, Universität Würzburg, Würzburg, Germany., Targosz BS; Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany., Jacobs L; Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany., Knorn AM; Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany., Slawska J; Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany., Platzbecker U; Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl-Gustav-Carus, Technische Universität, Dresden, Germany., Germing U; Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany., Langer C; Department of Internal Medicine III, University of Ulm, Ulm, Germany., Knop S; Division of Hematology and Medical Oncology, Department of Internal Medicine II, Würzburg University Medical Center, Würzburg, Germany., Einsele H; Division of Hematology and Medical Oncology, Department of Internal Medicine II, Würzburg University Medical Center, Würzburg, Germany., Peschel C; Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Haass C; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.; Biomedical Center, Ludwig-Maximilians University Munich, Munich, Germany., Keller U; Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Schmid B; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany., Götze KS; Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Kuster B; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Proteomics and Bioanalytics, Technische Universität München, Freising, Germany.; Center for Integrated Protein Science Munich (CIPSM), Freising, Germany., Bassermann F; Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.

Publikováno v: Nature medicine [Nat Med] 2016 Jul; Vol. 22 (7), pp. 735-43. Date of Electronic Publication: 2016 Jun 13.